Does BICALUTAMIDE Cause Malignant neoplasm progression? 352 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 352 reports of Malignant neoplasm progression have been filed in association with BICALUTAMIDE (Bicalutamide). This represents 8.7% of all adverse event reports for BICALUTAMIDE.
352
Reports of Malignant neoplasm progression with BICALUTAMIDE
8.7%
of all BICALUTAMIDE reports
52
Deaths
43
Hospitalizations
How Dangerous Is Malignant neoplasm progression From BICALUTAMIDE?
Of the 352 reports, 52 (14.8%) resulted in death, 43 (12.2%) required hospitalization, and 4 (1.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BICALUTAMIDE. However, 352 reports have been filed with the FAERS database.
What Other Side Effects Does BICALUTAMIDE Cause?
Prostatic specific antigen increased (322)
Drug ineffective (268)
Fatigue (258)
Prostate cancer (258)
Asthenia (223)
Hot flush (219)
Off label use (171)
Disease progression (169)
Anaemia (164)
Death (164)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which BICALUTAMIDE Alternatives Have Lower Malignant neoplasm progression Risk?
BICALUTAMIDE vs BICTEGRAVIR
BICALUTAMIDE vs BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE
BICALUTAMIDE vs BIFIDOBACTERIUM LONGUM
BICALUTAMIDE vs BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS
BICALUTAMIDE vs BILASTINE